David J Keeling

Title: David J Keeling: Innovator in Pharmaceutical Chemistry

Introduction

David J Keeling is a notable inventor based in Harpenden, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of two patents to his name, Keeling's work focuses on developing compounds that address critical health issues.

Latest Patents

Keeling's latest patents include "Substituted Quinoline Derivatives" and "Substituted Quinazoline Derivatives for Use in Gastrointestinal Diseases." The first patent describes inhibitors of bone resorption, specifically highlighting the compound 1-(2-methylphenyl)imidazo[4,5-c]quinoline hydrochloride. The second patent involves 2,4-diaminoquinazoline compounds, which act as inhibitors of the H⁺ K⁺ ATPase enzyme, proving useful for treating diseases of the stomach related to excessive gastric acid secretion. A notable compound from this invention is 2-[2-methyl-4-fluorophenyl)amino]-4-(N-methylphenylamino)quinazoline.

Career Highlights

Throughout his career, David J Keeling has worked with prominent companies in the pharmaceutical industry. He has been associated with SmithKline Beecham, Intercredit B.V., and Smith Kline & French Laboratories Limited. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Keeling has collaborated with esteemed colleagues, including Robert John Ife and Thomas H Brown. These partnerships have fostered innovation and have been instrumental in the development of his patented compounds.

Conclusion

David J Keeling's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to improving health outcomes. His work continues to influence the field and showcases the importance of research and development in medicine.